BACKGROUND: Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients. AIM: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls. METHODS: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied. RESULTS: Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated. CONCLUSIONS: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.
BACKGROUND:Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients. AIM: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBSpatients compared with healthy controls. METHODS: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied. RESULTS: Immune activation was more frequently observed in IBSpatients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBSpatients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated. CONCLUSIONS: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.
Authors: Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita Journal: Gastroenterology Date: 2017-07-13 Impact factor: 22.682
Authors: A Gupta; S Cole; J S Labus; S Joshi; T J Nguyen; L A Kilpatrick; K Tillisch; B D Naliboff; L Chang; E A Mayer Journal: Neurogastroenterol Motil Date: 2017-02-12 Impact factor: 3.598
Authors: Mark McOmber; Danny Rafati; Kevin Cain; Sridevi Devaraj; Erica M Weidler; Margaret Heitkemper; Robert J Shulman Journal: Clin Gastroenterol Hepatol Date: 2019-05-14 Impact factor: 11.382
Authors: Sarah L Hagerty; Jarrod M Ellingson; Timothy B Helmuth; L Cinnamon Bidwell; Kent E Hutchison; Angela D Bryan Journal: Perspect Psychol Sci Date: 2019-06-07
Authors: Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper Journal: J Gastroenterol Date: 2014-01-17 Impact factor: 7.527